Adaptive Biotechnologies (Adaptive Biotechnologies) LT-Debt-to-Total-Asset : 0.14 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Adaptive Biotechnologies LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Adaptive Biotechnologies's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.14.

Adaptive Biotechnologies's long-term debt to total assets ratio increased from Dec. 2022 (0.12) to Dec. 2023 (0.14). It may suggest that Adaptive Biotechnologies is progressively becoming more dependent on debt to grow their business.

Adaptive Biotechnologies LT-Debt-to-Total-Asset Historical Data

The historical data trend for Adaptive Biotechnologies's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptive Biotechnologies LT-Debt-to-Total-Asset Chart

Adaptive Biotechnologies Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.04

0.09

0.12

0.14

Adaptive Biotechnologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.12	0.12	0.12	0.13	0.14

Adaptive Biotechnologies LT-Debt-to-Total-Asset Calculation

Adaptive Biotechnologies's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	89.388	/	661.134
	=	0.14

Adaptive Biotechnologies's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	89.388	/	661.134
	=	0.14

Adaptive Biotechnologies (NAS:ADPT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Adaptive Biotechnologies LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Adaptive Biotechnologies's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Adaptive Biotechnologies (Adaptive Biotechnologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (NAS:ADPT) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

1HM:Germany

Address

1165 Eastlake Avenue East, Seattle, WA, USA, 98109

Website

https://www.adaptivebiotech.com

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease ("MRD") in patients with multiple myeloma ("MM"), B cell acute lymphoblastic leukemia ("ALL") and chronic lymphocytic leukemia ("CLL") and is also available as a CLIA-validated laboratory developed test ("LDT") for patients with other lymphoid cancers, including diffuse large B-cell lymphoma ("DLBCL").

Executives

Kyle Piskel	officer: Principal Accounting Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Nitin Sood	officer: Chief Commercial Officer, MRD	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Tycho Peterson	officer: Chief Financial Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109
R Mark Adams	officer: Chief Operating Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Michelle Renee Griffin	director	19723 NE 65TH LANE, KIRKLAND WA 98033
Stacy L Taylor	officer: SVP and General Counsel	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVENUE E SUITE 200, SEATTLE WA 98102
Leslie Trigg	director	C/O OUTSET MEDICAL, 1830 BERING ROAD, SAN JOSE CA 95112
Kevin T Conroy	director	5505 ENDEAVOR LANE, MADISON WI 53719
Robert Hershberg	director	3005 FIRST AVENUE, SEATTLE WA 98121
Peter M Neupert	director	13920 SE EASTGATE WAY, STE 300, BELLEVUE WA 98005
Sharon Benzeno	officer: Chief Commercial Ofc Imm Med	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Harlan S Robins	officer: Chief Scientific Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Francis Lo	officer: Chief People Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Michael J Pellini	director	222 DUTTON MILL RD, WILLISTOWN PA 19380
Chad M Robins	director, officer: CEO and Chairman	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102